Loading clinical trials...
Loading clinical trials...
Evaluation of the Immunogenicity and Safety of a Commercially Available Vaccine When Co-administered With GlaxoSmithKline Biologicals' HPV Vaccine (580299) in Healthy Female Subjects.
Conditions
Interventions
Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)
Engerix™
Locations
2
Belgium
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
La Louvière, Belgium
Start Date
March 11, 2008
Primary Completion Date
June 20, 2008
Completion Date
June 18, 2009
Last Updated
January 3, 2020
NCT06535139
NCT05266898
NCT05148559
NCT06002282
NCT04180462
NCT06854354
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions